First National Corp MA ADV Raises Position in Amgen Inc. (NASDAQ:AMGN)

First National Corp MA ADV raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 9.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,420 shares of the medical research company’s stock after purchasing an additional 210 shares during the period. First National Corp MA ADV’s holdings in Amgen were worth $697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. OFI Invest Asset Management purchased a new stake in shares of Amgen in the third quarter worth approximately $26,000. Briaud Financial Planning Inc purchased a new stake in shares of Amgen in the third quarter worth approximately $26,000. VisionPoint Advisory Group LLC purchased a new stake in shares of Amgen in the second quarter worth approximately $28,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Amgen in the first quarter worth approximately $28,000. Finally, Providence Capital Advisors LLC purchased a new stake in shares of Amgen in the third quarter worth approximately $30,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on AMGN shares. Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $264.00 to $320.00 in a research note on Thursday, December 21st. SVB Leerink cut Amgen from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $324.00 to $318.00 in a research note on Wednesday, February 7th. Leerink Partnrs cut Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Morgan Stanley dropped their price objective on Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 7th. Finally, StockNews.com cut Amgen from a “buy” rating to a “hold” rating in a research note on Tuesday, March 19th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $295.30.

Amgen Stock Up 0.6 %

Amgen stock opened at $288.05 on Thursday. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The stock has a market capitalization of $154.37 billion, a price-to-earnings ratio of 22.92, a PEG ratio of 2.66 and a beta of 0.58. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The business has a fifty day moving average price of $290.44 and a 200-day moving average price of $280.66.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business’s quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter last year, the firm earned $4.09 EPS. Equities research analysts forecast that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.12%. Amgen’s dividend payout ratio (DPR) is 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.